Immunomodulatory Effect of Aza-Spirocyclic Frameworks

Immunomodulators play a central role in the treatment of cancer and immune-mediated disorders. Small-molecule immunomodulators are particularly attractive due to their structural diversity, pharmacological versatility, and potential for oral administration. This study aimed to investigate the immunomodulatory potential of newly synthesized aza-spirocyclic derivatives.

A series of novel aza-spirocyclic compounds was evaluated for cytotoxicity in RAW264.7 murine macrophages. Immunomodulatory activity was assessed by quantifying nitric oxide (NO) production and profiling pro- and anti-inflammatory cytokines in macrophages and murine splenocytes. In vitro anti-inflammatory effects were further examined using a lipopolysaccharide (LPS)-induced inflammation model. Mechanistic insights were explored using molecular docking and immuno-informatics analyses.

All compounds were non-toxic at the tested concentrations. Most derivatives failed to induce NO production, indicating an absence of danger-associated molecular pattern (DAMP)-like activity. Several compounds significantly reduced the pro-inflammatory cytokine interleukin-6 (IL-6) while increasing the anti-inflammatory cytokine IL-10 in vitro. In the LPS-induced inflammation model, four compounds notably suppressed IL-6 and enhanced IL-10 expression. The binding affinities obtained from docking, along with in vitro validation of these compounds on Janus kinases (JAKs) signaling, suggested that compounds AS8 and AS10 modulated inflammatory signaling pathways.

The synthesized aza-spirocyclic derivatives exhibit promising anti-inflammatory profiles, characterized by IL-6 suppression and IL-10 enhancement. These findings position aza-spirocyclic scaffolds as candidates for the development of next-generation small-molecule immunomodulators.